Jan 14, 2020 / 12:30AM GMT
Cory William Kasimov - JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst
All right. Good afternoon, everyone. My name is Cory Kasimov. I'm the senior large-cap biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, Moderna. Here to present for Moderna is the CEO, Stéphane Bancel, and please note that following Stéphane's presentation, there's a breakout just across the hall in the Georgian room. So with that, Stéphane?
Stéphane Bancel - Moderna, Inc. - CEO & Director
Thank you, Cory. Good afternoon, everybody. Thank you for joining us. Before starting, let me remind you, we'll be making forward-looking statements and there are risks associated with investing in Moderna, which you can find on the SEC website or on our website.
So let me start by capping a little bit 2019. The key highlights before looking at the future, what's coming. So today Moderna has 20 program in development. So of course, I'm not going to go through all of these. You can find the slides on our website. But
Moderna Inc at JPMorgan Healthcare Conference Transcript
Jan 14, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers